ARPO Aerpio Pharmaceuticals Inc

EQS-News: Patrimonium Private Equity announces the sale of CCS Group

EQS Group-News: Dynamics Group AG / Key word(s): Investment/Mergers & Acquisitions
Patrimonium Private Equity announces the sale of CCS Group

01.11.2018 / 08:57


Press Release

Patrimonium Private Equity announces the sale of CCS Group

Baar/Echandens, 1 November 2018 - ZM Opportunity II L.P., a fund advised by Patrimonium Private Equity (formerly Zurmont Madison Private Equity) has sold its shareholding in CCS Group Holding AG ("CCS") to GPV International A/S ("GPV"), Denmark's largest EMS (Electronics Manufacturing Service) company, which is owned by Danish industrial conglomerate Schouw & Co. The combination of the GPV and CCS Group will create one of the largest EMS companies in Europe with revenues of about EUR 350 million and 3,700 employees.

CCS Group was founded in Switzerland in 1985 and provides electronics sub-assembly solutions and finished products (box-build) to their customers in high-mix and low-volume series. Furthermore, CCS has its own product design and engineering unit as well as cable-harness manufacturing specialising in cable customisation. In 2011, Zurmont Madison Private Equity acquired a majority stake in CCS as part of a succession agreement. With the commitment and financial investment by the new owners CCS' expansion and growth strategy accelerated. In the last years, turnover has more than tripled to EUR 190 million in 2017 accompanied by significant jobs growth from around 1,000 employees to 2,300 employees.

The transaction agreed upon strengthens the market positions of both companies as GPV and CCS complement each other on three continents. Today, most of CCS' customers are based in the German-speaking parts of Europe whereas most of GPV's customers are headquartered in northern Europe. GPV has production facilities in Denmark, Mexico and Thailand, while CCS has production facilities in Switzerland, Germany, Austria, Slovakia, Sri Lanka and China. As such, the bigger organisation will have the power and capacity to take on a greater volume of jobs from the combined customer base and grow the business. The newly formed EMS group will take the name of GPV, and its head office will be in Denmark led by group CEO Bo Lybæk. CCS CEO Thomas Kaiser will continue to lead CCS and be responsible for its integration into the new group.

GPV's CEO Bo Lybæk said: "Together we will form an overall stronger EMS group: The combined organisation will stand stronger in the value chain versus the customers in both GPV and CCS markets. We see a big potential in staying focused on the HMLV (High-Mix/Low-Volume) segment."

Werner Schnorf, Managing Director of Patrimonium Private Equity, added: "It was an exciting challenge to accompany and support the development of the CCS Group into a new dimension over the past seven years. According to our buy and build strategy, we provided financial backing and our industrial know-how to consequently develop the company into well-positioned European EMS outsourcing partner. We are happy to pass our shareholding on to a committed partner who will continue to support the group in its further development in order to create an EMS leader in electronics focused on box-build and mechatronic products."

Launch of a new Private Equity Fund
With the sale of CCS, the last portfolio company of the ZM Opportunity II L.P. Fund has been successfully sold. Patrimonium Private Equity is launching a new buyout fund investing in mid-sized companies focusing on the topic consolidation, internationalization and digital transformation. A corresponding fundraising program has been recently launched.

For more information, please contact:
Francois Hutter, Media Relations
Email: , Telephone 8 Mobile 4
Werner Schnorf, Managing Director Patrimonium Private Equity
Email: , Telephone 3

About PATRIMONIUM
PATRIMONIUM is an independent Swiss alternative asset management company active in real estate, private debt, infrastructure and private equity. On behalf of institutional and private investors, PATRIMONIUM and its affiliates manage approx. CHF 3bn in assets. PATRIMONIUM employs over 50 investment professionals and operates offices in Echandens/Lausanne, Zurich and Baar/Zug.

About CCS Group
CCS Group was founded in Switzerland in 1985 under the name of Formatest AG. CCS Group specialises in electronics, cable harness manufacturing and system integration. The company is headquartered in Lachen, Switzerland, and operates production facilities in Switzerland, Germany, Austria, Slovakia, Sri Lanka and China. CCS Group expects revenues of CHF 240 million in 2018 and employs about 2,300 employees of which approx. 50% are based in Europe and the rest in Sri Lanka and in China.

About GPV
GPV was founded in 1961 and is today Denmark's largest electronics manufacturer. GPV is a customer-driven EMS business (Electronics Manufacturing Services) providing advanced electronic solutions and mechatronics to customers all over the world. Headquartered in Denmark, GPV has production facilities in Denmark (Tarm and Aars), Thailand (Bangkok) and Mexico (Guadalajara). GPV reported revenue of DKK 1.2 billion in 2017 and has about 1,400 employees of which 85% are based in Thailand and Mexico. Since 1 April 2016, GPV has been a portfolio company of the Danish industrial conglomerate Schouw & Co.
-group.com and



End of Corporate News


740331  01.11.2018 

fncls.ssp?fn=show_t_gif&application_id=740331&application_name=news&site_id=research_pool
EN
01/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch